Unravelling a kinase inhibitor's elusive antimalarial mode of action.

A repurposed human kinase inhibitor was developed by Nardella et al. as a highly effective antimalarial with minimal cross resistance. A wide range of analyses implicated a Plasmodium kinase and haemoglobin digestion as potential drug targets, but the true mode of action remains ambiguous, highlighting the hurdles involved in drug target identification.